{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:31:41Z","timestamp":1740133901297,"version":"3.37.3"},"reference-count":17,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Identification of sentinel node (SN) metastases can set the adjuvant systemic therapy indication for stage III melanoma patients. For stage IIIA patients, a 1.0 mm threshold for the largest SN tumour diameter is used. Therefore, uniform reproducible measurement of its size is crucial. At present, the number of deposits or their microanatomical sites are not part of the inclusion criteria for adjuvant treatment. The goal of the current study was to show examples of the difficulty of measuring SN melanoma tumour diameter and teach how it should be measured. Histopathological slides of SN-positive melanoma patients were retrieved using the Dutch Pathology Registry (PALGA). Fourteen samples with the largest SN metastasis around 1.0 mm were uploaded via tele-pathology and digitally measured by 12 pathologists to reflect current practice of measurements in challenging cases. Recommendations as educational examples were provided. Microanatomical location of melanoma metastases was 1 subcapsular, 2 parenchymal and 11 combined. The smallest and largest difference in measurements were 0.24 mm and 4.81 mm, respectively. 11\/14 cases (78.6%) showed no agreement regarding the 1.0 mm cut-off. The median discrepancy for cases \u22645 deposits was 0.5 mm (range 0.24\u20130.60, n=3) and 2.51 mm (range 0.71\u20134.81, n=11) for cases with \u22656 deposits. Disconcordance in measuring SN tumour burden is correlated with the number of deposits. Awareness of this discordance in challenging cases, for example, cases with multiple small deposits, is important for clinical management. Illustrating cases to reduce differences in size measurement are provided.<\/jats:p>","DOI":"10.1136\/jcp-2023-209354","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:25:38Z","timestamp":1708453538000},"page":"372-377","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes"],"prefix":"10.1136","volume":"77","author":[{"given":"Annelien E","family":"Laeijendecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-4670","authenticated-orcid":false,"given":"Mary-Ann","family":"El Sharouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Stathonikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clothaire P E","family":"Spoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A","family":"van de Wiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik J E","family":"Eijken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijne","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antien L","family":"Mooyaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Szumera-Cieckiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mihic-Probst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Massi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senada","family":"Koljenovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llucia","family":"Alos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-2745","authenticated-orcid":false,"given":"Paul J","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C J","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willeke","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2024053002531522000_77.6.372.1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6513-7"},{"key":"2024053002531522000_77.6.372.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"2024053002531522000_77.6.372.3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for Melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2024053002531522000_77.6.372.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2024053002531522000_77.6.372.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2024053002531522000_77.6.372.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"2024053002531522000_77.6.372.7","unstructured":"Fda . FDA web site. Available: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adjuvant-treatment-melanoma [Accessed 29 Mar 2022]."},{"key":"2024053002531522000_77.6.372.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.08.015"},{"key":"2024053002531522000_77.6.372.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.03.010","article-title":"An updated European Organisation for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for Melanoma","volume":"114","author":"Cook","year":"2019","journal-title":"Eur J Cancer"},{"key":"2024053002531522000_77.6.372.10","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1002\/cncr.24298","article-title":"Interobserver reproducibility of histologic parameters of Melanoma deposits in sentinel lymph nodes: implications for management of patients with Melanoma","volume":"115","author":"Murali","year":"2009","journal-title":"Cancer"},{"key":"2024053002531522000_77.6.372.11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jso.26095","article-title":"Challenges in sentinel node pathology in the era of adjuvant treatment","volume":"122","author":"Franke","year":"2020","journal-title":"J Surg Oncol"},{"key":"2024053002531522000_77.6.372.12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune Checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024053002531522000_77.6.372.13","doi-asserted-by":"crossref","unstructured":"Leeneman B , Uyl-de Groot CA , Aarts MJB , et al . Healthcare costs of metastatic cutaneous Melanoma in the era of Immunotherapeutic and targeted drugs. Cancers (Basel) 2020;12. doi:10.3390\/cancers12041003","DOI":"10.3390\/cancers12041003"},{"key":"2024053002531522000_77.6.372.14","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/971816"},{"key":"2024053002531522000_77.6.372.15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2021.03.001","article-title":"High Discordance rate in assessing sentinel node positivity in cutaneous Melanoma: expert review may reduce unjustified adjuvant treatment","volume":"149","author":"El Sharouni","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024053002531522000_77.6.372.16","doi-asserted-by":"crossref","unstructured":"Dewar DJ , Newell B , Green MA , et al . The Microanatomic location of metastatic Melanoma in sentinel lymph nodes predicts Nonsentinel lymph node involvement. J Clin Oncol 2004:3345\u20139.","DOI":"10.1200\/JCO.2004.12.177"},{"key":"2024053002531522000_77.6.372.17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CMR.0000000000000643","article-title":"External validation of the American joint committee on cancer 8th edition Melanoma staging system: who needs adjuvant treatment","volume":"30","author":"Madu","year":"2020","journal-title":"Melanoma Res"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2023-209354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T18:30:57Z","timestamp":1717093857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2023-209354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jcp-2023-209354"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2023-209354","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}